The company reported a net loss of $2.2 million, or 5 cents a share, compared with $5.9 million, or 27 cents a share, in the same quarter last year. Analysts polled by FactSet had expected a loss of 21 cents a share.
Net patient service revenue rose nearly five-fold to $1.2 million from $242,000 a year earlier, driven by growth at Hope Therapeutics clinics. That result fell short of Wall Street’s $1.3 million revenue estimate. NRx Pharmaceuticals, which is based in Florida, operates six Hope Therapeutics clinics focused on interventional psychiatry.
The company said the Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine in October, ahead of the Nov. 10 goal date. NRx began selling the drug the week of Nov. 9. The approval was the company’s first for a drug.





Comments (0)
No comments yet. Be the first!